1
|
Heloury J, Bouguéon G, Deljehier T, Jourand A, Berroneau A, Crauste-Manciet S. Automation of Aseptic Sterile Preparation: Risk Analysis and Productivity Comparison with Manual Process. Pharmaceutical Technology in Hospital Pharmacy 2019. [DOI: 10.1515/pthp-2019-0001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Two automation methods for aseptic preparation in hospital pharmacy, robot and peristaltic pump, were compared to manual process both for risk analysis using Failure Modes Effects and Criticality Analysis (FMECA) method and for productivity using time analysis grids built for each process.
The results obtained with the different workflow organizations showed that the worst-case conditions for productivity was production “on demand” of tailor-made preparations. in that case, the manual process was not significantly different from the robotic process (p-value=0.72). For the standardized preparations, the semi-automatic process preparing a batch from bulk solution from “to be reconstituted” drugs was significantly superior to the robotic process preparing repetitive series of doses (p-value<0.01). Productivity of the robot was dramatically increased when the robot performed standardized preparations either from ready to use solutions or mixed cycles due to the robot design. When different processes were FMECA analyzed for risk analysis the robotic process was found as the safer process in comparison to others with a total of Criticality Indexes of 1060, 719, 656 for manual, semi-automatic and robot, respectively. Except for the robotic, semi-automatic and manual processes needed additional IT control systems to limit the risk of failures.
Collapse
Affiliation(s)
- Jeanne Heloury
- Pharmaceutical Technology Department , Bordeaux University Hospital , Bordeaux , France
| | - Guillaume Bouguéon
- Pharmaceutical Technology Department , Bordeaux University Hospital , Bordeaux , France
- ARNA laboratory ChemBioPharm U1212 INSERM – UMR 5320 CNRS , Bordeaux University , Bordeaux , France
| | - Thomas Deljehier
- Pharmaceutical Technology Department , Bordeaux University Hospital , Bordeaux , France
| | - Audrey Jourand
- Quality department , Bordeaux University Hospital , Bordeaux , France
| | - Aude Berroneau
- Pharmaceutical Technology Department , Bordeaux University Hospital , Bordeaux , France
| | - Sylvie Crauste-Manciet
- Pharmaceutical Technology Department , Bordeaux University Hospital , Bordeaux , France
- ARNA laboratory ChemBioPharm U1212 INSERM – UMR 5320 CNRS , Bordeaux University , Bordeaux , France
| |
Collapse
|
2
|
Deljehier T, Bouguéon G, Heloury J, Moreno V, Berroneau A, Crauste-Manciet S. Simulation program of a cytotoxic compounding robot for monoclonal antibodies and anti-infectious sterile drug preparation. J Oncol Pharm Pract 2019; 25:1873-1890. [DOI: 10.1177/1078155218823911] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The aim of this study was to develop a specific simulation program for the validation of a cytotoxic compounding robot, KIRO® Oncology, for the preparation of sterile monoclonal antibodies and anti-infectious drugs. The impact of excipient formulations was clearly measured using simulation accuracy tests with worst case excipient (i.e. viscous, foaming) and allowed to correct the robotic settings prior to real production. Corrections brought accuracies within the acceptable range of ±5%. KIRO® Oncology robot has also the capacity of self-cleaning and a simulation combining media fill test, and environmental monitoring was able to validate the aseptic process including simulation of worst case conditions and highlighting the areas not accessible to self-cleaning to be corrected by additional manual cleaning measures. The risk of chemical contamination was simulated by using fluorescent dye of the process with high-risk excipient formulation and overpressure vials. Quality control reliability was simulated by using a model drug, and final concentration was determined by high-performance liquid chromatography-ultraviolet detection. Finally, productivity was simulated using different models of production showing the impact of the type of drug, the number of vials and the poor standardization of the process.
Collapse
Affiliation(s)
- Thomas Deljehier
- Pharmaceutical Technology Department, Bordeaux University Hospital, Bordeaux, France
| | - Guillaume Bouguéon
- Pharmaceutical Technology Department, Bordeaux University Hospital, Bordeaux, France
- ARNA Laboratory ChemBioPharm U1212 INSERM, UMR 5320 CNRS Bordeaux University, Bordeaux, France
| | - Jeanne Heloury
- Pharmaceutical Technology Department, Bordeaux University Hospital, Bordeaux, France
| | - Valérie Moreno
- Biomedical Department, Bordeaux University Hospital, Bordeaux, France
| | - Aude Berroneau
- Pharmaceutical Technology Department, Bordeaux University Hospital, Bordeaux, France
| | - Sylvie Crauste-Manciet
- Pharmaceutical Technology Department, Bordeaux University Hospital, Bordeaux, France
- ARNA Laboratory ChemBioPharm U1212 INSERM, UMR 5320 CNRS Bordeaux University, Bordeaux, France
| |
Collapse
|
3
|
Deljehier T, Pariente A, Miremont-Salamé G, Haramburu F, Nguyen L, Rubin S, Rigothier C, Théophile H. Rhabdomyolysis after co-administration of a statin and fusidic acid: an analysis of the literature and of the WHO database of adverse drug reactions. Br J Clin Pharmacol 2018; 84:1057-1063. [PMID: 29337401 DOI: 10.1111/bcp.13515] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Revised: 12/16/2017] [Accepted: 01/02/2018] [Indexed: 12/21/2022] Open
Abstract
Following a severe case of rhabdomyolysis in our University Hospital after a co-administration of atorvastatin and fusidic acid, we describe this interaction as this combination is not clearly contraindicated in some countries, particularly for long-term treatment by fusidic acid. All cases of rhabdomyolysis during a co-administration of a statin and fusidic acid were identified in the literature and in the World and Health Organization database, VigiBase® . In the literature, 29 cases of rhabdomyolysis were identified; mean age was 66 years, median duration of co-administration before rhabdomyolysis occurrence was 21 days, 28% of cases were fatal. In the VigiBase® , 182 cases were retrieved; mean age was 68 years, median duration of co-administration before rhabdomyolysis was 31 days and 24% of cases were fatal. Owing to the high fatality associated with this co-administration and the long duration of treatment before rhabdomyolysis occurrence, fusidic acid should be used if there is no appropriate alternative, as long as statin therapy is interrupted for the duration of fusidic acid therapy, and perhaps a week longer. Rarely will interruption of this sort have adverse consequences for the patient.
Collapse
Affiliation(s)
- Thomas Deljehier
- Department of Medical Pharmacology, Regional Pharmacovigilance Centre, CHU Bordeaux, F-33000, Bordeaux, France.,University of Bordeaux, Bordeaux, France
| | - Antoine Pariente
- Department of Medical Pharmacology, Regional Pharmacovigilance Centre, CHU Bordeaux, F-33000, Bordeaux, France.,University of Bordeaux, Bordeaux, France.,team Pharmacoepidemiology, University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, F-33000, Bordeaux, France
| | - Ghada Miremont-Salamé
- Department of Medical Pharmacology, Regional Pharmacovigilance Centre, CHU Bordeaux, F-33000, Bordeaux, France.,team Pharmacoepidemiology, University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, F-33000, Bordeaux, France
| | - Françoise Haramburu
- Department of Medical Pharmacology, Regional Pharmacovigilance Centre, CHU Bordeaux, F-33000, Bordeaux, France.,team Pharmacoepidemiology, University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, F-33000, Bordeaux, France
| | - Linh Nguyen
- University of Bordeaux, Bordeaux, France.,Department of Nephrology, Transplantation, Dialysis and Apheresis, CHU Bordeaux, Bordeaux, France.,INSERM, BioTis, UMR 1026, University of Bordeaux, Bordeaux, France
| | - Sébastien Rubin
- University of Bordeaux, Bordeaux, France.,Department of Nephrology, Transplantation, Dialysis and Apheresis, CHU Bordeaux, Bordeaux, France.,INSERM, BioTis, UMR 1026, University of Bordeaux, Bordeaux, France
| | - Claire Rigothier
- University of Bordeaux, Bordeaux, France.,Department of Nephrology, Transplantation, Dialysis and Apheresis, CHU Bordeaux, Bordeaux, France.,INSERM, BioTis, UMR 1026, University of Bordeaux, Bordeaux, France
| | - Hélène Théophile
- Department of Medical Pharmacology, Regional Pharmacovigilance Centre, CHU Bordeaux, F-33000, Bordeaux, France
| |
Collapse
|